Content about Pharmaceutical industry

August 15, 2010

The Food and Drug Administration may rescind its approval of a drug used to treat...

August 15, 2010

A lot of generic drug companies have conducted business in the branded drug market on...

SOMERSET, N.J. A lot of generic drug companies have conducted business in the branded drug market on the side for a long time, with Teva Pharmaceutical Industries and Watson Pharmaceuticals standing out as good examples. But lately, some branded drug companies have sought to get into generics as well.

 

Meda Pharmaceuticals, the U.S. subsidiary of Swedish drug maker Meda A.B., recently decided to create its own generics subsidiary, calling it Wallace Pharmaceuticals, senior marketing director John White told Drug Store News.

 

August 15, 2010

The Food and Drug Administration has approved a prefilled dual-chamber syringe made by Pfizer for...

NEW YORK The Food and Drug Administration has approved a prefilled dual-chamber syringe made by Pfizer for treating hemophilia, Pfizer said.

 

The FDA approved the syringe for administering the drug Xyntha (antihemophilic factor [recombinant]) for hemophilia A. The drug is used to prevent and control bleeding episodes in patients.

 

 

August 12, 2010

The U.S. District Court for the District of New Jersey has ruled against drug maker...

INDIANAPOLIS The U.S. District Court for the District of New Jersey has ruled against drug maker Eli Lilly in its patent infringement case against generic drug maker Actavis regarding a drug used to treat attention deficit hyperactivity disorder, Lilly said.

 

The court ruled that a method-of-use patent covering the drug, Strattera (atomoxetine), was invalid. The patent was set to expire in May 2017.

 

 

August 12, 2010

In these times of trillion-dollar spending bills and massive deficits, $16 billion may not seem...

WHAT IT MEANS AND WHY IT'S IMPORTANT In these times of trillion-dollar spending bills and massive deficits, $16 billion may not seem like all that much. But it’s enough to throw another critical lifeline to states coping with the ever-rising costs of Medicaid health assistance to the poor and unemployed –– and to thousands of community pharmacies that have to provide prescription services to those millions of Americans.

August 12, 2010

The Global Market Development Center on Friday partnered with Recall InfoLink to offer product recall...

August 12, 2010

The companies working on more than half of the mental illness drugs under development are...

WASHINGTON The companies working on more than half of the mental illness drugs under development are clustered in four U.S. states, according to research by the largest lobby for the drug industry.

 

The Pharmaceutical Research and Manufacturers of America compiled a study showing that of the 313 drugs, 192 are under development by companies in New York, New Jersey, North Carolina and California. The drugs are in clinical trials or under review by the Food and Drug Administration, PhRMA said.

 

 

August 11, 2010

The main lobbying group for the generic drug industry said federal authorities erred in projecting...

August 11, 2010

The CEO of Ranbaxy Labs will step down next week, the Indian generic drug maker...

August 9, 2010

Nabi Biopharmaceuticals will receive an $8 million payment from British drug maker GlaxoSmithKline following a...

August 9, 2010

Generic drug maker Watson Pharmaceuticals posted strong sales for second quarter 2010, according to an...

August 9, 2010

French drug maker Sanofi-Aventis and a division of San Diego-based nonprofit community health system Scripps...

August 9, 2010

Israeli drug maker Teva Pharmaceutical Industries has finished its $5 billion acquisition of German generic...

August 8, 2010

Anglo-Swedish drug maker AstraZeneca has settled 17,500 product liability cases involving one of its drugs,...

August 4, 2010

Generic drug maker Cornerstone Therapeutics has filed for approval of a treatment for cold symptoms,...

CARY, N.C. Generic drug maker Cornerstone Therapeutics has filed for approval of a treatment for cold symptoms, Cornerstone said Thursday.

 

The drug maker announced the filing of an application with the Food and Drug Administration for CRTX-067 (chlorpheniramine polistirex and hydrocodone polistirex) oral suspension, a generic version of UCB’s Tussionex.

 

 

August 3, 2010

Pfizer had a big increase in sales and a modest increase in profits during second...

August 3, 2010

Generic drug maker Watson Pharmaceuticals has appointed two new executives this week....

August 2, 2010

French drug maker Sanofi-Aventis has made an offer for Genzyme, according to published reports....

August 2, 2010

Teva Pharmaceutical Industries got closer to finishing its $5 billion acquisition of German drug maker...

August 2, 2010

Victory Pharma has finished acquiring virtually all the assets of MiddleBrook Pharmaceuticals, Victory said Tuesday....

August 1, 2010

Merck had global sales of $11.3 billion and profits of $752 million during second quarter...

August 1, 2010

The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals...

SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals for treating migraine attacks, Sagent said Monday.

 

The FDA approved Sagent’s sumatriptan succinate injection in the 6 mg per 0.5 milliliter strength. The drug is used to treat acute migraine attacks and cluster headache episodes.

 

 

Sumatriptan is a generic version of GlaxoSmithKline’s Imitrex. Injectable sumatriptan had $22 million in sales in 2009, according to IMS Health.

July 22, 2010

The Food and Drug Administration has approved the first generic version of a Sanofi-Aventis injected...

SILVER SPRING, Md. The Food and Drug Administration has approved the first generic version of a Sanofi-Aventis injected drug used to treat deep vein thrombosis, the agency said Friday.

 

The FDA approved generic enoxaparin sodium, a version of Sanofi’s Lovenox, developed under a collaboration between Momenta Pharmaceuticals and Sandoz, the generics division of Swiss drug maker Novartis.

 

 

July 21, 2010

Several generic drug makers have settled with Forest Labs and German drug maker Merz Pharma...

July 21, 2010

A reported excess of a quarter billion dollars is a good case for increasing use...

WASHINGTON A reported excess of a quarter billion dollars is a good case for increasing use of generic drugs under the Medicaid program, according to the main lobby for the generic drug industry.

 

Responding to a report by conservative think tank the American Enterprise Institute that identified $271 million in wasteful Medicaid spending, the Generic Pharmaceutical Association said it was a “compelling case” for increasing generic drug utilization.